Patents by Inventor Xiangping Qian

Xiangping Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20180125855
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: November 7, 2017
    Publication date: May 10, 2018
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20180072688
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: August 14, 2017
    Publication date: March 15, 2018
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS
    Publication number: 20180064637
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 10, 2017
    Publication date: March 8, 2018
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • Certain chemical entities, compositions, and methods
    Patent number: 9908866
    Abstract: Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 6, 2018
    Assignee: NeuPharma, Inc.
    Inventors: Yong-Iiang Zhu, Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20180022714
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: June 8, 2017
    Publication date: January 25, 2018
    Inventors: Xiangping QIAN, Yong-liang ZHU
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 9849139
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 26, 2017
    Assignee: NeuPharma, Inc.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20170362271
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: May 4, 2017
    Publication date: December 21, 2017
    Inventor: Xiangping Qian
  • BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER
    Publication number: 20170340630
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.
    Type: Application
    Filed: January 6, 2017
    Publication date: November 30, 2017
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20170334859
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 23, 2017
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 9822081
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: November 21, 2017
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 9814735
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: November 14, 2017
    Assignee: SUZHOU NEUPHARMA CO., LTD
    Inventor: Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20170283395
    Abstract: Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 5, 2017
    Inventors: Yong-liang Zhu, Xiangping Qian
  • SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS
    Publication number: 20170281621
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 20, 2017
    Publication date: October 5, 2017
    Inventors: Luke W. ASHCRAFT, Gustave BERGNES, Scott COLLIBEE, Chihyuan CHUANG, Jeff GARDINA, Bradley P. MORGAN, Alex R. MUCI, Xiangping QIAN, Jeffrey WARRINGTON, Zhe YANG, Pu-Ping LU, Antonio ROMERO
  • Amino-pyrimidine skeletal muscle modulators
    Patent number: 9730886
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: August 15, 2017
    Assignee: Cytokinetics, Inc.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Substituted quinoxalines as B-raf kinase inhibitors
    Patent number: 9725421
    Abstract: Described herein are kinase inhibitors represented by Formula I: and pharmaceutical compositions thereof, for use in the treatment of cancer.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: August 8, 2017
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 9707202
    Abstract: Chemical entities that are curcumin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: July 18, 2017
    Assignee: NeuPharma, Inc.
    Inventor: Xiangping Qian
  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20170196881
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: November 22, 2016
    Publication date: July 13, 2017
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20170183316
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: November 4, 2016
    Publication date: June 29, 2017
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 9688635
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: June 27, 2017
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-liang Zhu
  • Certain steroids and methods for using the same in the treatment of cancer
    Patent number: 9676813
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: June 13, 2017
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian